Old problems, new tools: ZR2 in older patients with DLBCL

unique to MCL or also seen in other types of lymphoma resistant to BTK inhibitors.Nonetheless, this work could mark the start of a new era of understanding resistance to BTK inhibitors in MCL, moving beyond genetic alterations.More research is needed to understand what triggers giant cell formation and any liabilities this creates that could be leveraged for more effective combination therapies.This could allow BTK inhibitor therapy to be more effective in a broader swath of patients with MCL and for a longer response duration among those who do respond to treatment.